作者
Pier Luigi Zinzani, Alessandro Pulsoni, Alessio Perrotti, Simona Soverini, Francesco Zaja, Amalia De Renzo, Sergio Storti, Vito Michele Lauta, Luciano Guardigni, Patrizia Gentilini, Alessandra Tucci, Anna Lia Molinari, Marco Gobbi, Brunangelo Falini, Pier Paolo Fattori, Fabrizio Ciccone, Lapo Alinari, Maurizio Martelli, Stefano Pileri, Sante Tura, Michele Baccarani
发表日期
2004/7/1
期刊
Journal of clinical oncology
卷号
22
期号
13
页码范围
2654-2661
出版商
American Society of Clinical Oncology
简介
Purpose
Promising new therapeutic options for follicular lymphoma (FL) include fludarabine plus mitoxantrone (FM) and the mouse/human anti-CD20 antibody, rituximab. We performed a randomized comparative trial of FM with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) front-line chemotherapy with and without sequential rituximab.
Patients and Methods
All previously untreated CD20+ FL patients presenting in 15 Italian cooperative institutions from October 1999 were randomly allocated to FM or CHOP. Following clinical or molecular restaging, patients in complete remission (CR) with bcl-2/IgH negativity (CR−) received no further treatment; those in CR with bcl-2/IgH positivity (CR+) received rituximab, as did those in partial remission (PR) with bcl-2/IgH negativity (PR−) or positivity (PR+); nonresponders (NR subgroup) were off study.
Results …
引用总数
学术搜索中的文章
PL Zinzani, A Pulsoni, A Perrotti, S Soverini, F Zaja… - Journal of clinical oncology, 2004